Stock Ratings / Health Care / IPSC / forecast

LCTX (29) CABA (42) FATE (40) OCGN (35) ⌘ Pro Terminal →

Century Therapeutics Inc. (IPSC) 12-Month Stock Forecast & Price Target Cone

$1.46 -2.67% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Century Therapeutics Inc. (IPSC) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $264.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-13.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IPSC)Realized 20D OHLCV Swing Band: ±12.5%

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your IPSC Position Size: $10,000

Shares at $1.46: 6849.3 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $0.98

$6,712

$-3,288 (-32.9%)

12M Consensus BaseTarget $1.26

$8,630

$-1,370 (-13.7%)

12M Bull Case BreakoutTarget $3.19

$21,849

+$11,849 (+118.5%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$1	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$3	69%	B
JP MorganUS Large-Cap Research	SELL	$1	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IPSC)

✓Walkthrough of IPSC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

IPSC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -36.24%▼ DESCENDING CHANNEL

2026-10-30O $1.46H $1.50L $1.37C $1.46VOL 951.1K

RES: $1.92SUP: $1.01SMA50: $1.74SMA200: $2.10

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IPSC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IPSC Butterfly Map → + Track IPSC →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on IPSC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IPSC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for IPSC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IPSC)

Health Care Rank #966 of 1016 ⚔️ LCTX vs IPSC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IPSC vs. LCTX, CABA, FATE, OCGN)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Century Therapeutics Inc. (IPSC) ranks #966 by composite RQD confidence (28/100, grade E) and #536 by equity capitalization ($264.4M). Within this direct 5-issuer industry benchmark cohort, IPSC leads on earnings valuation at N/A trailing P/E, while IPSC leads on capital efficiency and profitability with -14.1% ROIC and — gross margin. CABA currently holds the highest overall quantitative score in the immediate peer group at 42/100 (D-) compared with IPSC at 28/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
IPSC ACTIVE Century Therapeutics Inc.	E	28/100	—	—	-14.1%	-2.67%	$264.4M	Benchmark Subject
LCTX Lineage Cell Therapeutics Inc.	E	29/100	—	—	-35.0%	-0.96%	$260.5M	/lctx-vs-ipsc →
CABA Cabaletta Bio Inc.	D-	42/100	—	—	-35.0%	+4.28%	$268.7M	/caba-vs-ipsc →
FATE Fate Therapeutics Inc.	D-	40/100	—	—	-35.0%	0.00%	$260.0M	/fate-vs-ipsc →
OCGN Ocugen Inc.	D-	35/100	—	—	-35.0%	-4.15%	$252.4M	/ocgn-vs-ipsc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001850119

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Century Therapeutics Inc. (IPSC) reported GAAP revenue of $109.2M (+1556.8% vs. FY2024 revenue of $6.6M , and +4784.3% cumulative change since FY2023) , GAAP net income of -$9.6M, operating cash flow of -$103.9M, and free cash flow of -$104.7M (+5.0% YoY). On the balance sheet, IPSC closed FY2025 with $223.7M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$109.2M	-$9.6M	-$103.9M	-$104.7M	$223.7M	—
FY2024 (FY)	2024-12-31	$6.6M	-$126.6M	-$110.1M	-$110.3M	$353.2M	—
FY2023 (FY)	2023-12-31	$2.2M	-$136.7M	-$88.3M	-$88.3M	—	—

3. IPSC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IPSC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Century Therapeutics Inc. (NASDAQ: IPSC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $1.46 (-2.67% 1D, market cap $264.4M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, IPSC ranks #966 in composite RQD confidence.

How does IPSC compare to LCTX and CABA in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IPSC carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -14.1%. By comparison, LCTX (Lineage Cell Therapeutics Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $260.5M) and CABA (Cabaletta Bio Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $268.7M). Among the 5-stock peer group, IPSC leads on earnings multiple (N/A) while IPSC leads on capital efficiency (-14.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for IPSC?

Per IPSC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001850119), Century Therapeutics Inc. generated $109.2M in revenue (+1556.8% YoY), -$9.6M in net income, and -$104.7M in free cash flow against $223.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is IPSC trading relative to its 50-day, 200-day, and 52-week technical levels?

IPSC last traded at $1.46 (-2.67% on volume of 1,445,895 shares), positioning the stock -16.09% below its 50-day simple moving average ($1.74) and -30.48% below its 200-day simple moving average ($2.10). Across its 52-week range of $0.44 to $3.04, IPSC sits at the 39.2% percentile with a 14-day RSI of 44.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.28 to $1.64).

IPSC Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is IPSC's 12-month stock price target?

Century Therapeutics Inc. (IPSC) carries a 12-month consensus base price target of $1.26 (-13.7% from $1.46), with a bull-case target of $3.19 and a bear-case floor of $0.98.

Is IPSC stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates IPSC E (Strong Sell — SELL) with an RQD Confidence score of 28/100.

Direct Sub-Reports: IPSC RQD Cockpit IPSC 12M Forecast IPSC Earnings & Move IPSC Dividends & DRIP IPSC Insiders & 13F IPSC Whale Options IPSC Profit Sankey IPSC News & Why